Buy Thymosin Alpha 1 | Thymosin Alpha-1 5 mg

Buy Thymosin Alpha 1, Thymosin Alpha-1 5 mg. A synthetic peptide with potent immunomodulatory qualities, thymosin Alpha-1 (5 mg) is frequently used as an adjuvant treatment for immunological malfunction, cancer, and viral infections. It is a promising treatment for diseases like cancer, COVID-19, and chronic hepatitis since it boosts both innate and adaptive immunity.

• The 28-amino acid peptide known as Thymosin Alpha-1 (Tα1) was first identified in thymic tissue.
• In more than 35 countries, it is sold pharmaceutically as Zadaxin for the treatment of chronic hepatitis B and as an immune booster.
• Tα1 is a real immune modulator that balances both hyperactive and underactive immunological responses, in contrast to simple immune stimulants.

Buy Thymosin Alpha 1 | Mechanism of Action

• Immune cell activation: Promotes the development of NK cells, dendritic cells, and T cells (CD4+, CD8+).
• Toll-like Receptor (TLR) Engagement: Increases the production of cytokines (IL-2, IFN-α, and IFN-γ) via activating TLR2/3/4/7/9 pathways.
• Restores Immune Competence: Boosts innate immune surveillance, enhances antigen presentation, and reverses T-cell fatigue.

Buy Thymosin Alpha 1 | Clinical Uses

• Viral Infections: Used in HIV experiments and demonstrated to lower mortality in severe COVID-19 cases; approved for chronic HBV/HCV.
• Cancer Therapy: Increases survival and boosts the effectiveness of checkpoint inhibitors in non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC).
• Meta-analyses of sepsis indicate better immunological markers and decreased mortality.
• Immunodeficiency & Vaccines: Enhances vaccination responses in immunocompromised individuals and reinstates immunological function in people who have been suppressed by chemotherapy or aging.

Administration & Dosage

• Usually, 5 mL of bacteriostatic water is used to reconstitute a 5 mg vial, resulting in a concentration of 1 mg/mL.
• 900 µg (90 units) twice a week for 12 weeks is the standard dosage.
• Alternative Research Dosage: 1.6 mg twice a week in HIV or cancer protocols.
• Administration: Subcutaneous injection (upper arm, thigh, or abdomen).
• Cycle Protocols: Usually 12 weeks on and 4 weeks off, followed by a reevaluation of immunological markers.

Profile of Safety

• Comprehensive Clinical Data: Used pharmaceutically for decades and examined in Phase III trials involving more than 4,400 people.
• Well Tolerated: No significant safety signals throughout long-term use; adverse event rates are similar to those of a placebo.
• No Tumorigenesis or Autoimmunity Evidence: Safe even in populations with severe infections and cancer.

Comparison: Kisspeptin-10 vs Thymosin Alpha-1